Login Register Cart 0
Review Article

SKY59，一种用于补体介导疾病的新型回收抗体

卷 27, 期 25, 2020

页: [4157 - 4164] 页: 8

弟呕挨: 10.2174/0929867326666191016115853

价格: $65

摘要

背景：补体系统通常有助于预防微生物感染，但也可能与各种疾病的发作有关。依库丽单抗对补体成分5（C5）的抑制作用已导致溶血性夜间血红蛋白尿（PNH）患者的溶血显着减少，血栓栓塞事件的减少以及存活率的提高。但是，由于血浆中C5丰富，依库丽单抗需要频繁静脉输注，并且某些患者可能仍会经历突破性溶血。这篇综述介绍了有关回收技术的最新知识，并讨论了新型回收抗体SKY59对PNH和补体介导的疾病的潜在治疗作用。 方法：通过使用回收技术，我们创建了一种新型的抗C5抗体SKY59，能够与pH依赖地结合C5。 结果：在猴群中，SKY59强烈抑制C5和补体活性，作用时间明显长于传统抗体。 SKY59还显示出对C5变体p.Arg885His的抑制作用，而依库丽单抗并未抑制这种突变患者的补体活性。 结论：SKY59是一种有前途的抗C5生物制剂，与目前的疗法相比具有显着的优势，例如作用时间长和抗C5变异体的功效。

关键词: 回收技术，抗体疗法，药代动力学，补体系统，C5，阵发性夜间血红蛋白尿。

« Previous Next »
[1]
Serruto, D.; Rappuoli, R.; Scarselli, M.; Gros, P.; van Strijp, J.A. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat. Rev. Microbiol., 2010, 8(6), 393-399.
[http://dx.doi.org/10.1038/nrmicro2366] [PMID: 20467445]
[2]
Holers, V.M. Complement and its receptors: new insights into human disease. Annu. Rev. Immunol., 2014, 32, 433-459.
[http://dx.doi.org/10.1146/annurev-immunol-032713-120154] [PMID: 24499275]
[3]
Merle, N.S.; Church, S.E.; Fremeaux-Bacchi, V.; Roumenina, L.T. Complement system part I - molecular mechanisms of activation and regulation. Front. Immunol., 2015, 6, 262.
[http://dx.doi.org/10.3389/fimmu.2015.00262] [PMID: 26082779]
[4]
Hill, A.; DeZern, A.E.; Kinoshita, T.; Brodsky, R.A. Paroxysmal nocturnal haemoglobinuria. Nat. Rev. Dis. Primers, 2017, 3, 17028.
[http://dx.doi.org/10.1038/nrdp.2017.28] [PMID: 28516949]
[5]
Jokiranta, T.S. HUS and atypical HUS. Blood, 2017, 129(21), 2847-2856.
[http://dx.doi.org/10.1182/blood-2016-11-709865] [PMID: 28416508]
[6]
Sharma, V.R. Paroxysmal nocturnal hemoglobinuria: pathogenesis, testing, and diagnosis. . Clinical advances in hematology & oncology: H&O, 2013, 11(Suppl)13(9), 2-8.
[7]
Hillmen, P.; Young, N.S.; Schubert, J.; Brodsky, R.A.; Socié, G.; Muus, P.; Röth, A.; Szer, J.; Elebute, M.O.; Nakamura, R.; Browne, P.; Risitano, A.M.; Hill, A.; Schrezenmeier, H.; Fu, C.L.; Maciejewski, J.; Rollins, S.A.; Mojcik, C.F.; Rother, R.P.; Luzzatto, L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med., 2006, 355(12), 1233-1243.
[http://dx.doi.org/10.1056/NEJMoa061648] [PMID: 16990386]
[8]
Zuber, J.; Fakhouri, F.; Roumenina, L.T.; Loirat, C.; Frémeaux-Bacchi, V. French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol., 2012, 8(11), 643-657.
[http://dx.doi.org/10.1038/nrneph.2012.214] [PMID: 23026949]
[9]
Igawa, T.; Ishii, S.; Tachibana, T.; Maeda, A.; Higuchi, Y.; Shimaoka, S.; Moriyama, C.; Watanabe, T.; Takubo, R.; Doi, Y.; Wakabayashi, T.; Hayasaka, A.; Kadono, S.; Miyazaki, T.; Haraya, K.; Sekimori, Y.; Kojima, T.; Nabuchi, Y.; Aso, Y.; Kawabe, Y.; Hattori, K. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol., 2010, 28(11), 1203-1207.
[http://dx.doi.org/10.1038/nbt.1691] [PMID: 20953198]
[10]
Henne, K.R.; Ason, B.; Howard, M.; Wang, W.; Sun, J.; Higbee, J.; Tang, J.; Matsuda, K.C.; Xu, R.; Zhou, L.; Chan, J.C.; King, C.; Piper, D.E.; Ketchem, R.R.; Michaels, M.L.; Jackson, S.M.; Retter, M.W. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. J. Pharmacol. Exp. Ther., 2015, 353(1), 119-131.
[http://dx.doi.org/10.1124/jpet.114.221242] [PMID: 25653417]
[11]
Lammerts van Bueren, J.J.; Bleeker, W.K.; Bøgh, H.O.; Houtkamp, M.; Schuurman, J.; van de Winkel, J.G.; Parren, P.W. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res., 2006, 66(15), 7630-7638.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-4010] [PMID: 16885363]
[12]
Cosson, V.F.; Ng, V.W.; Lehle, M.; Lum, B.L. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother. Pharmacol., 2014, 73(4), 737-747.
[http://dx.doi.org/10.1007/s00280-014-2400-5] [PMID: 24519752]
[13]
Okimura, K.; Maeta, K.; Kobayashi, N.; Goto, M.; Kano, N.; Ishihara, T.; Ishikawa, T.; Tsumura, H.; Ueno, A.; Miyao, Y.; Sakuma, S.; Kinugasa, F.; Takahashi, N.; Miura, T. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am. J. Transplant., 2014, 14(6), 1290-1299.
[http://dx.doi.org/10.1111/ajt.12678] [PMID: 24731050]
[14]
Martin, P.L.; Cornacoff, J.; Prabhakar, U.; Lohr, T.; Treacy, G.; Sutherland, J.E.; Hersey, S.; Martin, E. Reviews preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-alpha in Cynomolgus macaques. J. Immunotoxicol., 2005, 1(3), 131-139.
[http://dx.doi.org/10.1080/15476910490894904] [PMID: 18958646]
[15]
Haringman, J.J.; Gerlag, D.M.; Smeets, T.J.; Baeten, D.; van den Bosch, F.; Bresnihan, B.; Breedveld, F.C.; Dinant, H.J.; Legay, F.; Gram, H.; Loetscher, P.; Schmouder, R.; Woodworth, T.; Tak, P.P. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum., 2006, 54(8), 2387-2392.
[http://dx.doi.org/10.1002/art.21975] [PMID: 16869001]
[16]
Byrd, J.C.; O’Brien, S.; Flinn, I.W.; Kipps, T.J.; Weiss, M.; Rai, K.; Lin, T.S.; Woodworth, J.; Wynne, D.; Reid, J.; Molina, A.; Leigh, B.; Harris, S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res., 2007, 13(15 Pt 1), 4448-4455.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-1463]
[17]
Xiao, J.J.; Krzyzanski, W.; Wang, Y.M.; Li, H.; Rose, M.J.; Ma, M.; Wu, Y.; Hinkle, B.; Perez-Ruixo, J.J. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J., 2010, 12(4), 646-657.
[http://dx.doi.org/10.1208/s12248-010-9222-0] [PMID: 20737261]
[18]
Jayson, G.C.; Mulatero, C.; Ranson, M.; Zweit, J.; Jackson, A.; Broughton, L.; Wagstaff, J.; Hakansson, L.; Groenewegen, G.; Lawrance, J.; Tang, M.; Wauk, L.; Levitt, D.; Marreaud, S.; Lehmann, F.F.; Herold, M.; Zwierzina, H. European Organisation for Research and Treatment of Cancer (EORTC). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur. J. Cancer, 2005, 41(4), 555-563.
[http://dx.doi.org/10.1016/j.ejca.2004.11.021] [PMID: 15737560]
[19]
Finkelman, F.D.; Madden, K.B.; Morris, S.C.; Holmes, J.M.; Boiani, N.; Katona, I.M.; Maliszewski, C.R. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol., 1993, 151(3), 1235-1244.
[PMID: 8393043]
[20]
Rathanaswami, P.; Roalstad, S.; Roskos, L.; Su, Q.J.; Lackie, S.; Babcook, J. Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem. Biophys. Res. Commun., 2005, 334(4), 1004-1013.
[http://dx.doi.org/10.1016/j.bbrc.2005.07.002] [PMID: 16038881]
[21]
Bradbury, A.R.; Sidhu, S.; Dübel, S.; McCafferty, J. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol., 2011, 29(3), 245-254.
[http://dx.doi.org/10.1038/nbt.1791] [PMID: 21390033]
[22]
Dall’Acqua, W.F.; Kiener, P.A.; Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem., 2006, 281(33), 23514-23524.
[http://dx.doi.org/10.1074/jbc.M604292200] [PMID: 16793771]
[23]
Mircic, M.; Kavanaugh, A. The clinical efficacy of tocilizumab in rheumatoid arthritis. Drugs Today (Barc), 2009, 45(3), 189-197.
[http://dx.doi.org/10.1358/dot.2009.45.3.1343794] [PMID: 19436841]
[24]
Ghetie, V.; Ward, E.S. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol., 2000, 18, 739-766.
[http://dx.doi.org/10.1146/annurev.immunol.18.1.739] [PMID: 10837074]
[25]
Yeung, Y.A.; Leabman, M.K.; Marvin, J.S.; Qiu, J.; Adams, C.W.; Lien, S.; Starovasnik, M.A.; Lowman, H.B. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J. Immunol., 2009, 182(12), 7663-7671.
[http://dx.doi.org/10.4049/jimmunol.0804182] [PMID: 19494290]
[26]
Zalevsky, J.; Chamberlain, A.K.; Horton, H.M.; Karki, S.; Leung, I.W.; Sproule, T.J.; Lazar, G.A.; Roopenian, D.C.; Desjarlais, J.R. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol., 2010, 28(2), 157-159.
[http://dx.doi.org/10.1038/nbt.1601] [PMID: 20081867]
[27]
Robbie, G.J.; Criste, R.; Dall’acqua, W.F.; Jensen, K.; Patel, N.K.; Losonsky, G.A.; Griffin, M.P. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob. Agents Chemother., 2013, 57(12), 6147-6153.
[http://dx.doi.org/10.1128/AAC.01285-13] [PMID: 24080653]
[28]
Fukuzawa, T.; Sampei, Z.; Haraya, K.; Ruike, Y.; Shida-Kawazoe, M.; Shimizu, Y.; Gan, S.W.; Irie, M.; Tsuboi, Y.; Tai, H.; Sakiyama, T.; Sakamoto, A.; Ishii, S.; Maeda, A.; Iwayanagi, Y.; Shibahara, N.; Shibuya, M.; Nakamura, G.; Nambu, T.; Hayasaka, A.; Mimoto, F.; Okura, Y.; Hori, Y.; Habu, K.; Wada, M.; Miura, T.; Tachibana, T.; Honda, K.; Tsunoda, H.; Kitazawa, T.; Kawabe, Y.; Igawa, T.; Hattori, K.; Nezu, J. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci. Rep., 2017, 7(1), 1080.
[http://dx.doi.org/10.1038/s41598-017-01087-7] [PMID: 28439081]
[29]
Davda, J.P.; Hansen, R.J. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs, 2010, 2(5), 576-588.
[http://dx.doi.org/10.4161/mabs.2.5.12833] [PMID: 20676036]
[30]
Wang, W.; Wang, X.; Doddareddy, R.; Fink, D.; McIntosh, T.; Davis, H.M.; Zhou, H. Mechanistic pharmacokinetic/target engagement/pharmacodynamics (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. AAPS J., 2014, 16(1), 129-139.
[http://dx.doi.org/10.1208/s12248-013-9545-8] [PMID: 24287601]
[31]
Sissons, J.G.; Liebowitch, J.; Amos, N.; Peters, D.K. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation. J. Clin. Invest., 1977, 59(4), 704-715.
[http://dx.doi.org/10.1172/JCI108689] [PMID: 845257]
[32]
Morgan, B.P.; Harris, C.L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov., 2015, 14(12), 857-877.
[http://dx.doi.org/10.1038/nrd4657] [PMID: 26493766]
[33]
Gatault, P.; Brachet, G.; Ternant, D.; Degenne, D.; Récipon, G.; Barbet, C.; Gyan, E.; Gouilleux-Gruart, V.; Bordes, C.; Farrell, A.; Halimi, J.M.; Watier, H. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs, 2015, 7(6), 1205-1211.
[http://dx.doi.org/10.1080/19420862.2015.1086049] [PMID: 26337866]
[34]
Nishimura, J.; Yamamoto, M.; Hayashi, S.; Ohyashiki, K.; Ando, K.; Brodsky, A.L.; Noji, H.; Kitamura, K.; Eto, T.; Takahashi, T.; Masuko, M.; Matsumoto, T.; Wano, Y.; Shichishima, T.; Shibayama, H.; Hase, M.; Li, L.; Johnson, K.; Lazarowski, A.; Tamburini, P.; Inazawa, J.; Kinoshita, T.; Kanakura, Y. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med., 2014, 370(7), 632-639.
[http://dx.doi.org/10.1056/NEJMoa1311084] [PMID: 24521109]
[35]
Langemeijer, S.; Nishimura, J-I.; Weston-Davies, W.; Nunn, A. Miles.; Kanakura, Y.; Mackie, J., Ian.; Muss, P. C5 Polymorphism in a Dutch patient with paroxysmal nocturnal hemoglobinuria (PNH) and no Asian ancestry, resistant to eculizumab, but in vitro sensitive to coversin. Blood, 2015, 126, 1209.
[http://dx.doi.org/10.1182/blood.V126.23.1209.1209]
[36]
Schatz-Jakobsen, J.A.; Zhang, Y.; Johnson, K.; Neill, A.; Sheridan, D.; Andersen, G.R. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J. Immunol., 2016, 197(1), 337-344.
[http://dx.doi.org/10.4049/jimmunol.1600280] [PMID: 27194791]

Rights & Permissions Print Cite
Article Metrics
84
17
2
© 2024 Bentham Science Publishers | Privacy Policy